The effect of adjuvant chemotherapy on stage IV (T4N1-3M0 and T1-3N3M0) gastric cancer.
OBJECTIVE
The optimal chemotherapeutic strategy for gastric cancer patients has not been determined, especially with respect to stage and the curability of gastric cancer. The aim of this study was to evaluate the results of adjuvant chemotherapy on stage IV (T4N1-3M0 and T1-3N3M0) gastric cancer after curative gastrectomy between a chemotherapy (CTX) group and non-chemotherapy (non-CTX) group.


METHODS
Among 1,760 patients who underwent gastric surgery by 1 surgeon in a single institution, 162 stage IV gastric cancer patients with curative gastrectomy were analyzed retrospectively, excluding patients with TanyNanyM1. One hundred twenty-five patients who received different chemotherapeutic regimens were compared to 37 patients who did not receive chemotherapy for reasons of old age or according to their expressed desire.


RESULTS
The clinicopathologic factors which showed a clinically significant difference between the two groups were age and histology, which were not associated with patient survival. The CTX group was younger, and had a larger proportion of undifferentiated gastric cancers than the non-CTX group. The mode of treatment failure revealed no significant difference between the CTX and non-CTX groups. The 1, 3, and 5-year disease-free survival and the 1, 3, and 5-year disease-specific survival of the CTX group were 63.9%, 38.4%, and 32.0%, and 85.4%, 52.3%, and 39.6%, respectively, which were more favorable than the non-CTX group (p=0.015 and p=0.001, respectively). Postoperative adjuvant CTX was an independent risk factor for disease-specific survival of stage IV (T4N1-3M0 and T1-3N3M0) gastric cancer patients after curative gastrectomy by multivariate analysis (odds ratio=2.153; 95% confidence interval=1.349-3.435; p=0.001).


CONCLUSIONS
Adjuvant CTX may be associated with survival benefit for younger patients with stage IV (T4N1-3M0 and T1-3N3M0) gastric cancer with undifferentiated histology after curative gastrectomy. A randomized controlled trial to reveal the effect of stage-specific adjuvant chemotherapy should be conducted.
Ha
Tae Kyung
TK
Department of Surgery, Hanyang University College of Medicine, Seoul, Korea.
Jung
Min Sung
MS
Lee
Kang Hong
KH
Lee
Kyeong Geun
KG
Kwon
Sung Joon
SJ
Lancet Oncol. 2006 Jun;7(6):515-6
16750502
Am J Clin Oncol. 1982 Dec;5(6):649-55
7165009
Br J Cancer. 2001 Apr 6;84(7):878-80
11286464
Int J Cancer. 2004 May 1;109(5):737-41
14999783
Br J Surg. 2007 Dec;94(12):1468-76
17948223
J Clin Oncol. 2004 Aug 15;22(16):3408-19
15199089
Br J Surg. 1996 Feb;83(2):156-61
8689153
N Engl J Med. 2001 Sep 6;345(10):725-30
11547741
Tumori. 2002 Jan-Feb;88(1):21-7
12004845
N Engl J Med. 2006 Jul 6;355(1):11-20
16822992
J Natl Cancer Inst. 2008 Mar 19;100(6):388-98
18334706
Am Surg. 2007 Apr;73(4):359-66
17439029
Dis Colon Rectum. 2008 May;51(5):503-7
18322753
Ann Oncol. 2002 Feb;13(2):299-307
11886009
Ann Oncol. 2000 Jul;11(7):837-43
10997811
Eur J Surg Oncol. 2008 Nov;34(11):1208-16
18353606
CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1
10200776
Semin Surg Oncol. 2003;21(1):23-9
12923913
J Clin Oncol. 2003 Jun 15;21(12):2282-7
12805327
N Engl J Med. 2007 Nov 1;357(18):1810-20
17978289
J Clin Oncol. 1993 Aug;11(8):1441-7
8336183
Cancer Invest. 2008 Apr-May;26(3):317-25
18317973